Status:
UNKNOWN
Effect of Extracorporeal CO2 Removal in Stable Hypercapnic COPD Patients
Lead Sponsor:
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Conditions:
Chronic Obstructive Pulmonary Disease Patients
Chronic Respiratory Failure
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Chronic hypercapnic respiratory failure is common in stable COPD patients in a terminal phase of their disease In an attempt to correct or slow down the rate of rise of PaCO2, long-term noninvasive me...
Detailed Description
Chronic hypercapnic respiratory failure is common in stable COPD patients in a terminal phase of their disease In an attempt to correct or slow down the rate of rise of PaCO2, long-term noninvasive me...
Eligibility Criteria
Inclusion
- COPD ( FEV1/CVF \<0.70 post bronchodilation)
- stable PaCO2 \>55 mmHg non respondent to long-term NIV (at least one week). This means a decrease in PaCO2 during spontaneous breathing, at least 4 hrs after the termination of NIV, of\< 6%
- pH \> 7.35
- clinical stability
Exclusion
- Mean Arterial Pressure \< 60 mmHg
- contra-indication to heparin
- Body Mass Index (BMI) \> 30 kg/m2;
- presence of sleep apnea or overall syndrome
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT02260583
Start Date
October 1 2014
End Date
December 1 2018
Last Update
December 29 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
san'Orsola Malpighi Hospital, Bologna ITALY
Bologna, Italy, 40138